How to get a retatrutide prescription is a question many people with obesity are asking as early clinical trial data generates significant interest in this investigational triple-receptor agonist. Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from currently approved medicines such as semaglutide and tirzepatide. However, retatrutide has not received marketing authorisation from the MHRA and cannot be legally prescribed through standard NHS or private routes in the UK. This article explains what retatrutide is, how to discuss it with your doctor, who may be eligible, and how to stay safe within regulated pathways.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, but it has not received MHRA marketing authorisation and cannot be legally prescribed in the UK.

Retatrutide is an investigational weight management medicine currently undergoing clinical development. It belongs to a novel class of agents known as triple agonists, designed to target three hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-receptor mechanism distinguishes retatrutide from currently approved medicines such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist).

By activating all three receptors, retatrutide is hypothesised — based largely on preclinical and early-phase human data — to produce complementary effects on appetite suppression, energy expenditure, and glucose metabolism. GLP-1 receptor activation is associated with reduced appetite and slowed gastric emptying; GIP receptor activation may enhance insulin secretion and influence fat metabolism; and glucagon receptor activation is thought to increase energy expenditure. The precise contribution of each receptor pathway in humans remains under active investigation, and mechanistic descriptions should be understood as working hypotheses rather than established fact.

A Phase 2 randomised controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported mean placebo-adjusted weight reductions of up to approximately 24% over 48 weeks in adults with obesity. However, this was a relatively small, short-duration study, and long-term safety and cardiovascular outcomes have not yet been established. Key safety signals observed in the Phase 2 trial included gastrointestinal adverse effects (nausea, vomiting, diarrhoea, and constipation), increases in resting heart rate, and gallbladder-related events — consistent with the broader class of incretin-based therapies.

It is essential to understand that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), which is the body responsible for licensing medicines for use in the UK following the UK's departure from the European Union. The European Medicines Agency (EMA) holds a separate remit covering the European Economic Area (EEA) but does not authorise medicines for use in Great Britain. Retatrutide is not approved for clinical use in the UK, and Phase 3 trials are ongoing. It cannot be legally prescribed through standard NHS or private prescribing routes at this time.

How to Speak to a Doctor About Retatrutide

Speak to your GP or an obesity medicine specialist about currently licensed alternatives and ask about referral to a clinical trial, as this is the only legitimate UK access route for retatrutide.

If you are interested in retatrutide as a potential treatment option, the most appropriate first step is to have an open and informed conversation with your GP or a specialist in obesity medicine or endocrinology. It is important to approach this discussion with realistic expectations, given that retatrutide does not currently hold a UK marketing authorisation and is therefore not available as a standard prescription medicine.

When speaking to your doctor, it may be helpful to:

• Explain your weight management history, including previous treatments tried, their outcomes, and any underlying health conditions such as type 2 diabetes, cardiovascular disease, or obstructive sleep apnoea.

• Ask about currently approved alternatives. In the UK, Wegovy (semaglutide 2.4 mg weekly) is licensed specifically for weight management in adults with obesity or overweight with weight-related comorbidities, subject to NICE criteria (TA875). Ozempic (semaglutide) and Mounjaro (tirzepatide) are licensed for the treatment of type 2 diabetes; their use for weight management outside this indication is not routinely commissioned on the NHS. Your doctor can advise on which licensed options may be appropriate for you.

• Ask about referral to a specialist weight management service. NICE guidance (CG189) sets out a tiered approach to obesity management in the UK. Access to pharmacological treatment is typically provided within the context of a tier 3 or tier 4 specialist weight management service, alongside dietary, behavioural, and physical activity support.

• Enquire about clinical trial participation, as this is currently the only legitimate route through which retatrutide can be accessed in the UK. Your doctor may be able to refer you to a research centre conducting Phase 3 trials. You can also search for UK-based studies via the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk), as well as ClinicalTrials.gov and the ISRCTN registry.

• Avoid unregulated online sources that claim to offer retatrutide. These are likely to be operating outside legal and safety frameworks. If you are considering purchasing any medicine online, verify that the pharmacy is registered with the General Pharmaceutical Council (GPhC) using the GPhC online pharmacy register.

Honest, two-way communication with your healthcare provider is the safest and most effective approach when exploring new or investigational treatments.

Who May Be Eligible for a Retatrutide Prescription?

There are no formal UK prescribing eligibility criteria for retatrutide; access is only possible through clinical trials, where eligibility is determined by the specific trial protocol.

Because retatrutide does not currently hold regulatory approval in the UK, there are no formal prescribing eligibility criteria in the way that exist for licensed medicines. The following information is provided for context only and reflects the inclusion criteria used in the 2023 Phase 2 clinical trial (Jastreboff et al., NEJM 2023) — these are study-specific criteria and do not represent current UK prescribing standards or predict future NICE commissioning decisions.

In the Phase 2 clinical trial, participants generally met the following criteria:

• Body mass index (BMI) of 27 kg/m² or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, or obstructive sleep apnoea), or a BMI of 30 kg/m² or above without comorbidities.

• Adults aged 18 years and over.

• Individuals without severe gastrointestinal disease, active pancreatitis, or other contraindications relevant to incretin-based therapies.

• The trial excluded individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). This exclusion is consistent with standard practice for GLP-1 receptor agonist trials, based on rodent studies showing C-cell tumours with GLP-1 receptor agonists; it is a study-specific precaution and does not constitute a current UK contraindication for licensed GLP-1-based medicines.

For reference, NICE guidance on currently licensed weight management medicines — such as TA875 for semaglutide (Wegovy) — requires a BMI threshold, evidence of weight-related health conditions, and engagement with a specialist weight management programme. Any future NICE appraisal of retatrutide would be conducted independently and its outcome cannot be predicted at this stage.

Individuals who believe they may be suitable candidates for investigational weight management therapies should discuss clinical trial eligibility with their GP or a specialist. Participation in a regulated clinical trial remains the only currently legitimate route to accessing retatrutide in the UK, and eligibility is determined by the trial protocol rather than standard prescribing criteria.

Regulated Prescribing Pathways and Patient Safety in the UK

Retatrutide can only be accessed in the UK through an MHRA-authorised clinical trial; purchasing it from unregulated online sources is unsafe and carries both health and legal risks.

Patient safety is paramount when considering any medicine, and this is especially true for investigational drugs that have not yet completed the full regulatory approval process. In the UK, the MHRA is responsible for evaluating the safety, quality, and efficacy of medicines before they can be marketed and prescribed. Until retatrutide receives a positive marketing authorisation from the MHRA, it cannot be legally sold, supplied, or prescribed as a standard treatment in the UK.

The regulated routes through which retatrutide may currently be accessed in the UK are very limited:

• Participation in an approved clinical trial, conducted under a Clinical Trial Authorisation (CTA) issued by the MHRA. Trials can be identified via the NIHR 'Be Part of Research' portal, ClinicalTrials.gov, or the ISRCTN registry.

• Unlicensed 'specials', which are medicines manufactured or imported outside the standard licensing framework for individual named patients. This route is tightly regulated and is generally reserved for patients with serious or life-threatening conditions where no licensed alternative exists. It is very unlikely to apply to retatrutide for obesity management at this stage.

• The MHRA Early Access to Medicines Scheme (EAMS), which allows patients with life-threatening or seriously debilitating conditions to access promising unlicensed medicines before marketing authorisation. Given that existing licensed weight management options are available, retatrutide would not typically meet the threshold for EAMS access for obesity.

Patients should be strongly cautioned against purchasing retatrutide from unregulated online pharmacies or overseas suppliers. Such products may be counterfeit, contaminated, incorrectly dosed, or entirely different substances. The MHRA regularly issues warnings about unlicensed medicines sold online, and purchasing or importing unapproved medicines carries both health and legal risks. Always verify that any online pharmacy is registered with the General Pharmaceutical Council (GPhC) before making a purchase.

If you are currently using an approved weight management medicine and experience concerning symptoms — such as severe or persistent abdominal pain, persistent vomiting, a notably rapid heart rate, or signs of an allergic reaction — contact your GP promptly or call NHS 111. If you suspect you have experienced a side effect from any medicine, you can report this to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

For any new or emerging treatment, always seek guidance from a registered healthcare professional and verify that any prescriber is listed on the General Medical Council (GMC) register. Staying within regulated pathways is the safest way to explore new therapeutic options.

Frequently Asked Questions